Litjens & Brunt 2016: “How Toxic Is Ibogaine?” — Pharmacological Profile & Toxicity Review

Definition box

Definition: Ruud P.W. Litjens and Tibor M. Brunt (2016) published *How toxic is ibogaine?* in *Clinical Toxicology* (doi: 10.3109/15563650.2016.1138226; PMID 26807959; *Clin Toxicol* 54(4):297–302). This is a narrative pharmacological/toxicity review—not a new dosing RCT. From PubMed literature on ibogaine/noribogaine they summarize pharmacokinetics (CYP2D6 → noribogaine), multi-receptor actions, neurotoxicity themes (rat cerebellar Purkinje injury via inferior olive pathways at higher exposures), and especially cardiotoxicity via hERG potassium-channel blockade leading to QT prolongation and risk of torsades/ventricular arrhythmia. They note noribogaine’s prolonged presence after parent clearance and discuss human toxicological case material. Label this piece a review. It does not prove efficacy, does not authorize unsupervised use, and does not validate psychoactive IV ibogaine infusion. Ibogaine is U.S. Schedule I and not FDA-approved. Cardiac risk is the central practical takeaway.

Quotable answer (54 words)

Litjens and Brunt’s 2016 Clinical Toxicology review maps ibogaine’s PK, multi-receptor profile, cerebellar neurotoxicity themes, and hERG-linked cardiotoxicity with QT risk. It is a toxicity review—not a cure trial and not proof of psychoactive IV ibogaine infusion. Schedule I; demand ECG and screening before any supervised discussion.

Why this paper-spoke exists

When families ask “is ibogaine poisonous?”, marketing sites either panic or dismiss. Litjens & Brunt give a mid-2010s toxicology-frame answer: multi-system pharmacology with cardiac risk as the clinically decisive hazard and neurotoxicity as an important preclinical theme that must be dose-contextualized. Soft CTA: /safety-and-screening → /apply. Pair with Schep dose-safety commentary (/blog/schep-2016-ibogaine-poisoning), AE systematic review (/blog/ona-2022-ibogaine-adverse-events-review), and CV teaching (/blog/ibogaine-cardiovascular-complications-review).

What was reviewed

| Feature | Accurate description | |---------|----------------------| | Citation | Litjens R.P.W., Brunt T.M. How toxic is ibogaine? *Clin Toxicol (Phila)*. 2016;54(4):297–302. doi 10.3109/15563650.2016.1138226. PMID 26807959 | | Type | Narrative review of pharmacology & toxicity | | Methods (as reported) | PubMed search on ibogaine/noribogaine across mechanism, PK/PD, toxicology, cardiac, neurotoxic, human/animal, addiction, death keywords; authors report 382 unique refs (156 human-data related) and 14 detailed toxicological case reports highlighted | | Core domains | PK/PD; mechanisms; neurotoxicity; cardiotoxicity; clinical toxicity themes | | Route of evidence base | Mostly oral/clinic/case-report traditions; not a brand-IV trial | | What it is not | Efficacy meta-analysis; FDA approval; IV psychoactive proof |

Methods (plain language)

Reviewers did not dose patients. They synthesized published mechanism and toxicity literature so clinicians and toxicologists can answer “how does ibogaine hurt people?” Themes are only as strong as the underlying case reports, animal studies, and sparse controlled human data—hence this spoke repeatedly says review.

Key themes (no hype)

Pharmacokinetics / pharmacodynamics - Ibogaine is metabolized mainly by **CYP2D6** to **noribogaine** (10-hydroxyibogamine). - Noribogaine can remain at clinically relevant concentrations for **days** after parent ibogaine clears—relevant to delayed cardiac events. - Multi-receptor profile includes micromolar affinities at NMDA, κ- and μ-opioid, and sigma-2 sites, plus interactions spanning acetylcholine, serotonin, and dopamine systems and changes in expression of proteins such as BDNF, c-fos, and others discussed in the review.

Neurotoxicity themes - Rat data show neurodegeneration patterns linked to inferior olive stimulation with excitotoxic effects on **cerebellar Purkinje cells**. - Authors note neurotoxic signs were not found below certain animal dose thresholds (e.g., themes around <25 mg/kg i.p. in rats in the literature they synthesize)—**animal thresholds are not human clinic green lights**. - Noribogaine may be less neurotoxic than ibogaine in some preclinical comparisons—still not a human free pass.

Cardiotoxicity themes (family-critical) - **hERG** channel blockade delays cardiac repolarization → **QT/QTc prolongation** → substrate for **torsades de pointes** / ventricular arrhythmia. - Pre-existing heart disease is **not** required for every adverse cardiac event in the case literature the field discusses. - Delayed events after ingestion align with long-lived metabolite exposure narratives.

Honest reading: Toxicity reviews exist to prevent magical thinking—not to sell retreats.

How to read a 2016 toxicity review in 2026

Litjens & Brunt sit at a useful midpoint in the decade: after early hERG mechanistic reports and before later systematic AE reviews and 2024–2026 MISTIC-era headlines. Use it as a bridge document:

1. Mechanism literacy — CYP2D6 → noribogaine; multi-receptor promiscuity; hERG cardiotoxicity; cerebellar themes in rats.
2. Case-report humility — fourteen detailed toxicological cases in their harvest are signals, not a denominator for “risk percent.”
3. Update ladder — after this review, read Ona et al. AE systematic review (/blog/ona-2022-ibogaine-adverse-events-review), Brunt 2026 CV teaching (/blog/ibogaine-cardiovascular-complications-review), and clinical QTc cohorts (/blog/knuijver-2021-ibogaine-qtc-safety).
4. Marketing filter — any clinic that cites only “anti-addictive receptor story” while hiding QT should fail your diligence test.

Neurotoxicity headlines deserve the same nuance the authors attempt: animal Purkinje injury is real in the literature at higher exposures, yet anti-addictive animal doses and neurotoxic doses are not identical—and none of that licenses unmonitored human flood dosing.

Cardiac / YMYL practical checklist

Translate review themes into screening behavior:

1. Baseline and serial ECG / QTc attention (/blog/ibogaine-ecg-pre-infusion-checklist).
2. Electrolytes, drug–drug QT interactions, CYP2D6 context (/blog/ibogaine-drug-interactions-qtc, /blog/knuijver-2024-ibogaine-pk-cyp2d6).
3. Telemetry / ACLS-capable monitoring culture (/blog/ibogaine-telemetry-acls-monitoring).
4. Contraindication honesty (/blog/ibogaine-contraindications, /blog/ibogaine-pre-existing-heart-conditions).
5. Setting-factor discipline (/blog/ibogaine-setting-factors-safety-review-2023).

Route honesty: review of mostly oral/case literature ≠ IV brand proof

Litjens & Brunt synthesize pharmacology and toxicity across animal work and human case/clinic experience that is overwhelmingly not a modern psychoactive-IV brand RCT. Support IV (fluids, magnesium in some protocols) remains distinct from psychoactive IV ibogaine (/blog/ibogaine-oral-vs-iv, /blog/stanford-ibogaine-mistic). Entity: /what-is-ibogaine-infusion.

Limits and confounders

| Limit | Why it matters | |-------|----------------| | Narrative review | Selection/emphasis choices; not PRISMA systematic MA of efficacy | | Case-report dependence | Confounding by adulterants, dose uncertainty, comorbidities | | Animal neurotoxicity | Species and dose translation uncertain | | 2016 cutoff | Newer AE reviews and CV teaching should be co-read | | Not route-stratified brand evidence | Cannot prove IV psychoactive product claims |

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “Toxicity review = treatment works” | False | | “Knowing hERG means risk is solved” | Dangerously false | | “Review proves psychoactive IV efficacy” | False | | Cite as foundational mid-2010s toxicity/pharmacology map? | Yes |

No cure claims.

Soft CTA

If “how toxic?” is your real question, start with screening literacy—not forum dose folklore. Visit /safety-and-screening, then /apply only if exploring physician-supervised IV ibogaine infusion with eyes open. Entity: /what-is-ibogaine-infusion.

FAQ

What did Litjens & Brunt publish? A 2016 *Clinical Toxicology* review titled *How toxic is ibogaine?* (doi **10.3109/15563650.2016.1138226**).

Is it a clinical trial? No—it is a pharmacological/toxicity **review**.

What toxicity themes matter most clinically? **Cardiotoxicity** (hERG → QT/arrhythmia) is the decisive human risk theme; neurotoxicity is important preclinical context.

Does delayed risk after dosing make sense? Yes—noribogaine can persist days after parent clearance.

Does this prove IV ibogaine infusion is safe or effective? No on both counts.

Is ibogaine FDA-approved? No. Schedule I; not FDA-approved.

Should people with heart disease be extra careful? Yes—and even without known heart disease, QTc risk exists in the case literature (/blog/ibogaine-pre-existing-heart-conditions).

Where should screening start? /safety-and-screening, then /apply if appropriate.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Litjens & Brunt 2016 is a toxicity review—not personal access, not a cure claim, and not psychoactive IV ibogaine efficacy proof.

Sources (selected)

1. Litjens R.P.W., Brunt T.M. How toxic is ibogaine? *Clin Toxicol*. 2016;54(4):297–302. doi: 10.3109/15563650.2016.1138226. PMID: 26807959.
2. Schep L.J. et al. Ibogaine for treating drug dependence. What is a safe dose? *Drug Alcohol Depend*. 2016;166:1–5. doi: 10.1016/j.drugalcdep.2016.07.005.
3. Alper K. et al. hERG blockade by iboga alkaloids. *Cardiovasc Toxicol*. 2016;16(1):14–22. doi: 10.1007/s12012-015-9311-5.
4. Ona G. et al. Adverse events of ibogaine… *Psychopharmacology*. 2022. doi: 10.1007/s00213-021-05964-y.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).